Taiyen Biotech (Taiwan) Performance
| 1737 Stock | TWD 32.30 0.05 0.15% |
The entity has a beta of 0.0624, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Taiyen Biotech's returns are expected to increase less than the market. However, during the bear market, the loss of holding Taiyen Biotech is expected to be smaller as well. At this point, Taiyen Biotech has a negative expected return of -0.16%. Please make sure to validate Taiyen Biotech's standard deviation, jensen alpha, and the relationship between the coefficient of variation and information ratio , to decide if Taiyen Biotech performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Taiyen Biotech Co has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest abnormal performance, the Stock's basic indicators remain stable and the latest fuss on Wall Street may also be a sign of long-term gains for the venture sophisticated investors. ...more
| Begin Period Cash Flow | 1.5 B | |
| Total Cashflows From Investing Activities | -351.4 M |
Taiyen |
Taiyen Biotech Relative Risk vs. Return Landscape
If you would invest 3,565 in Taiyen Biotech Co on September 17, 2024 and sell it today you would lose (335.00) from holding Taiyen Biotech Co or give up 9.4% of portfolio value over 90 days. Taiyen Biotech Co is generating negative expected returns and assumes 0.474% volatility on return distribution over the 90 days horizon. Simply put, 4% of stocks are less volatile than Taiyen, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Taiyen Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Taiyen Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Taiyen Biotech Co, and traders can use it to determine the average amount a Taiyen Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.3279
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 1737 |
Estimated Market Risk
| 0.47 actual daily | 4 96% of assets are more volatile |
Expected Return
| -0.16 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.33 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Taiyen Biotech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Taiyen Biotech by adding Taiyen Biotech to a well-diversified portfolio.
Taiyen Biotech Fundamentals Growth
Taiyen Stock prices reflect investors' perceptions of the future prospects and financial health of Taiyen Biotech, and Taiyen Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Taiyen Stock performance.
| Return On Equity | 0.0642 | |||
| Return On Asset | 0.0346 | |||
| Profit Margin | 0.11 % | |||
| Operating Margin | 0.12 % | |||
| Current Valuation | 4.82 B | |||
| Shares Outstanding | 200 M | |||
| Price To Earning | 14.76 X | |||
| Price To Book | 1.00 X | |||
| Price To Sales | 1.61 X | |||
| Revenue | 4.1 B | |||
| EBITDA | 705.52 M | |||
| Cash And Equivalents | 2.14 B | |||
| Cash Per Share | 10.69 X | |||
| Total Debt | 53.08 M | |||
| Debt To Equity | 2.00 % | |||
| Book Value Per Share | 31.99 X | |||
| Cash Flow From Operations | 600.08 M | |||
| Earnings Per Share | 2.09 X | |||
| Total Asset | 8.47 B | |||
| Retained Earnings | 1.46 B | |||
| Current Asset | 2.48 B | |||
| Current Liabilities | 410 M | |||
About Taiyen Biotech Performance
Evaluating Taiyen Biotech's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Taiyen Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Taiyen Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Taiyen Biotech Co., Ltd. provides various health and beauty products under the TAIYEN brand Hong Kong, Taiwan, Mainland China, and Macau. The company was founded in 1952 and is based in Tainan, Taiwan. TAIYEN BIOTECH is traded on Taiwan Stock Exchange in Taiwan.Things to note about Taiyen Biotech performance evaluation
Checking the ongoing alerts about Taiyen Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Taiyen Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Taiyen Biotech generated a negative expected return over the last 90 days | |
| About 48.0% of the company shares are owned by insiders or employees |
- Analyzing Taiyen Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Taiyen Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Taiyen Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Taiyen Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Taiyen Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Taiyen Biotech's stock. These opinions can provide insight into Taiyen Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Taiyen Stock Analysis
When running Taiyen Biotech's price analysis, check to measure Taiyen Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Taiyen Biotech is operating at the current time. Most of Taiyen Biotech's value examination focuses on studying past and present price action to predict the probability of Taiyen Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Taiyen Biotech's price. Additionally, you may evaluate how the addition of Taiyen Biotech to your portfolios can decrease your overall portfolio volatility.